about
Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal modelThe E3 ubiquitin ligase UBE3A is an integral component of the molecular circadian clock through regulating the BMAL1 transcription factorTherapeutic antibodies, vaccines and antibodyomesSelf-assembling protein nanoparticles in the design of vaccinesHuman Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical CancerNatural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literatureAntibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice.Surveillance of human papilloma virus using reference laboratory data for the purpose of evaluating vaccine impact.Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade.Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination?Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18Research participation among Asian American women at risk for cervical cancer: exploratory pilot of barriers and enhancersThe economic burden of human papillomavirus-related precancers and cancers in Sweden.Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway.Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein.Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycleLong-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbitsPolyphenol extract of Phyllanthus emblica (PEEP) induces inhibition of cell proliferation and triggers apoptosis in cervical cancer cellsThe relationship between oral squamous cell carcinoma and human papillomavirus: a meta-analysis of a Chinese population (1994-2011).Prediction of protein-protein interactions between viruses and human by an SVM model.Would Worldwide Vaccination of Both Males and Females Against the Human Papillomavirus be a Worthy Investment?Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor virusesNothing but skin and bone.Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8(+) T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits.Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines.Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.Systems biology approaches to new vaccine development.Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India.Life saving treatment or giant experiment?Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensHuman papillomavirus vaccine: a boon or curse.Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.Establishment of a cottontail rabbit papillomavirus/HLA-A2.1 transgenic rabbit model.Hypoxia-inducible factor-1 facilitates cervical cancer progression in human papillomavirus type 16 transgenic mice.Gordon Wilson Lecture: Infectious Disease Causes of Cancer: Opportunities for Prevention and Treatment.Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.Conditionally replicating adenoviruses for cancer treatment.
P2860
Q21131365-72D3874D-88A7-4060-BDE6-8ECEF2C62416Q24294646-CE72ECA8-3414-4031-A70D-2895FA66B891Q24599662-0CDBCD79-3645-4741-ADA3-49C1C4FE2A54Q26767097-FEAB2206-A355-4B23-A87D-576931E3AD34Q26799484-C8035FB3-BBAD-41EF-B2AB-C95C999AE65DQ28072648-948FF501-C08A-4ED2-B611-6DB0BFED8C75Q30397437-90231C2E-20C4-4A21-BB47-5B71E6C45F81Q30884881-9983DC43-9A1F-44C6-A133-5932212A8850Q30981990-DC317C39-76B5-4758-A0A3-A238CDB5B518Q33327567-707878A9-003E-43FF-B2AA-753D8E2AC237Q33728320-A39C5F2B-E4C6-45B1-AC28-6750641A6FF2Q33743226-A4C7A7E8-1F4D-4CDE-9EAB-91136654B937Q33795099-DE4644B3-9A97-4B2C-BE23-D3F759CACC67Q33834660-4FB19842-5895-4252-98B1-E4F52886ACE6Q33851368-391B6D5E-7CDB-4B31-BBCC-7913C05E9312Q34007987-BFEA916A-7B30-4083-AB90-E86783BA1F88Q34075698-985F0E41-6DFC-4057-BC13-4C8B109F815DQ34121681-18F3784A-47D8-4FA7-9D96-8B6ADDCC76BCQ34154315-A26B1C5E-873E-41A4-BC4A-A659FAE3D4D4Q34193431-A708B154-4F64-454C-B891-1FE4570C5EB4Q34251582-8220B4A7-7026-4193-8714-E1A9062449C8Q34263251-EC7A97F5-7882-442E-90E5-4945D2C043E4Q34272619-CA85915F-9B05-4E67-AB44-65B2FEA2D264Q34381065-297C77DB-3650-46CF-A4F7-F533D52F2957Q34394771-7A4E5615-A049-407D-BCC5-5C79B669CC58Q34576635-5778B54A-E505-46C6-85E5-402B7BA33E61Q34730757-9D77E1FF-6415-4C53-8FCF-9EA28FDD817CQ34978068-0D5289E5-B835-4CEB-A1CE-5FAEC502EF39Q35042602-194F9087-B374-4955-97BF-7A44C5CAC20EQ35086204-0CE0BFE8-4CE0-44BA-924E-C7BB0F599282Q35112350-50B75E65-65C6-4F40-8704-E10FFB93ED58Q35742261-B0F825B6-B8C9-4464-A9DB-6523644D66F9Q35812875-01256FB4-6846-4DCB-9B95-6DA8CE89C875Q35886746-9C0D8EE7-1803-4E7E-A1B8-3D38965DA4A8Q35901974-78A0C2FC-E2D0-430E-B615-2B641DCF3770Q35914337-086D4D46-CAE2-4544-A9A0-1B87F9278610Q35916052-6E91B23B-77EB-4B60-9BA1-39E4BF573E43Q35933728-B12DC27A-50B8-4B64-B06D-D75A00BBFCACQ35947703-B3CC3D99-43F2-49D4-BA95-3001CDEB99E5Q35967313-836B5B21-EC89-492D-99E8-27B3BCCC030E
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Prophylactic human papillomavirus vaccines
@ast
Prophylactic human papillomavirus vaccines
@en
Prophylactic human papillomavirus vaccines
@nl
type
label
Prophylactic human papillomavirus vaccines
@ast
Prophylactic human papillomavirus vaccines
@en
Prophylactic human papillomavirus vaccines
@nl
prefLabel
Prophylactic human papillomavirus vaccines
@ast
Prophylactic human papillomavirus vaccines
@en
Prophylactic human papillomavirus vaccines
@nl
P2860
P3181
P356
P1476
Prophylactic human papillomavirus vaccines
@en
P2093
Douglas R Lowy
John T Schiller
P2860
P304
P3181
P356
10.1172/JCI28607
P407
P577
2006-05-01T00:00:00Z